M&A
Struggling Biotechs Face Harsh Market as Funding and Clinical Successes Dry Up in 2025
biotech layoffs; market downturn; funding challenges; clinical trial failures; investor sentiment; M&A slowdown; job cuts; biotech sector
Pfizer’s Bourla is ‘cautiously optimistic’ on tariffs, says M&A is on the table
Bourla, M&A, Pfizer, United States, TNFRSF19 gene, Policy, tariffs
Concentra’s Surprise Bid Disrupts Acelyrin-Alumis Merger Plans
Concentra Biosciences, Acelyrin, Alumis, merger disruption, unsolicited offer, biopharmaceutical industry, M&A
J&J’s Swift $14.6B Acquisition of Intra-Cellular Therapies: A CEO-Driven Deal
Johnson & Johnson, Intra-Cellular Therapies, acquisition, neuroscience, CAPLYTA, Joaquin Duato, pharmaceutical industry, M&A
Sage Therapeutics Rejects Biogen’s Acquisition Bid, Initiates Strategic Review
Sage Therapeutics, Biogen, acquisition rejection, strategic alternatives, ZURZUVAE, postpartum depression, pharmaceutical industry, M&A
Johnson & Johnson Acquires Intra-Cellular Therapies for $14.6 Billion, Expanding Neuroscience Portfolio
Johnson & Johnson, Intra-Cellular Therapies, Acquisition, Neuroscience, Lumateperone, CAPLYTA, Biopharma, M&A
Biotech Industry’s Turbulent Year: Fierce Biotech’s Top 10 Most-Read Stories of 2024
Biotech industry, layoffs, site shutdowns, FDA rejections, M&A deals, J.P. Morgan Healthcare Conference, biopharma trends
Navigating JPM Week 2024: Insights and Opportunities in Biopharma
JPM Week 2024, Biopharma, Industry Insights, Networking, Deal-making, Investment, M&A, IPOs, Regulatory Trends
Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals
Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty
Trump’s Return to the White House: Potential Implications for FDA and Biopharma M&A
Trump, FDA, Biopharma, M&A, Healthcare Policy, Robert F. Kennedy Jr.